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Idiopathic pulmonary fibrosis (IPF) is an independent risk factor for lung cancer (LC) development; 
however, there are currently no clinical guidelines for LC surveillance in IPF. This study aimed to 
investigate the cumulative incidence and survival outcomes of LC in IPF. Using the National Health 
Insurance Service database, including medical information on people aged ≥ 40 years between 2011 
and 2016, we identified IPF patients and confirmed the presence of comorbid LC. Patients diagnosed 
with IPF in 2011 were washed out, and mortality data were analyzed from 2012 to 2018. A total of 
7277 newly diagnosed IPF patients were identified among Korean citizens aged ≥ 40 years (about 50 
million people) between 2011 and 2016. Their average age was 71.5 years and 72.8% of them were 
male. The prevalence of LC in the IPF cases was 6.4%. The cumulative incidence rates of LC in IPF 
patients who did not have LC at the time of IPF diagnosis were 1.7%, 4.7%, and 7.0%, at 1, 3, and 
5 years, respectively. The median time from IPF diagnosis to LC development was 16.3 (Interquartile 
range, 8.2–28.8) months. The survival rate was significantly lower in the IPF with LC group than the 
IPF without LC group (P < 0.001). We concluded that IPF increases LC risk, and LC weakens survival 
outcomes in IPF. Close surveillance for LC development is mandatory for patients with IPF.
Abbreviations
HRCT  High-resolution computed tomography
ICD-10  International Classification of Disease, Tenth Revision
IPF  Idiopathic pulmonary fibrosis
LC  Lung cancer
NHIS  National Health Insurance Service
Idiopathic pulmonary fibrosis (IPF) is the most commonly occurring type of idiopathic interstitial pneumonia, 
characterized by chronic, progressive, fibrotic interstitial lung disease of an unknown cause and a histopathologi-
cal pattern of usual interstitial  pneumonia1,2. Epidemiological studies have revealed that IPF is an independent 
risk factor for lung cancer (LC) development after adjusting for shared risk factors. Hubbard et al. reported that 
the relative risk of developing LC in IPF is approximately eight times higher than in the general population, after 
adjusting for smoking history, based on United Kingdom healthcare  databases3. The prevalence of LC in IPF was 
reported to be 4.4–13%, and up to 48.2% in an autopsy study of 83 usual interstitial pneumonia  patients3–9. LC 
in IPF occurs more frequently in older male smokers and patients with combined  emphysema7,8,10. Comorbid 
LC significantly affects survival in IPF. The mortality values are higher among IPF patients with LC than IPF 
patients without  it11–13 and those with LC in the general  population8,14. Additionally, the treatment of LC itself 
can cause acute IPF exacerbation, which is the most lethal life-threatening complication of  IPF15–17.
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Despite the presence of notable epidemiologic associations between LC and IPF, and poor survival outcomes, 
there are currently no clinical guidelines for the screening of LC in IPF; since the natural history of IPF is highly 
variable, some patients show a relatively stable disease course without symptoms and, therefore, do not routinely 
visit  hospitals18. In the absence of an official recommendation for LC screening in IPF, a large number of IPF 
patients are diagnosed with advanced LC at the time of hospital visit due to symptom development over several 
years.
In this study, we investigated the demographic characteristics, cumulative incidence, and mortality associated 
with LC in IPF patients using nationwide data to suggest the direction of LC surveillance.
Results
Patient characteristics. A total of 7277 newly diagnosed IPF patients were identified between 2012 and 
2016. Their average age was 71.5 years and 72.8% of the study population was male. Of the IPF patients, 464 
(6.4%) were diagnosed with LC during the study period. The baseline demographics of the IPF patients with 
and without LC (IPF with LC and IPF without LC groups) were compared (Table 1). The proportion of men was 
lower (74.4% vs. 92.6%; P < 0.001) and average age was higher (71.5 vs. 70.6 years; P = 0.029) in the IPF without 
LC group than in the IPF with LC group. Similar proportions of urban and rural area-dwelling patients were 
observed in both the IPF without LC and IPF with LC groups. More than 40% of the patients in both groups 
were included in the fifth quintile of household income, the lowest socioeconomic status, and the distributions 
of household income were similar between the groups. Of the 464 patients in the IPF with LC group, 254 (54.7%) 
were diagnosed with IPF before LC, 127 (27.4%) had a simultaneous diagnosis of IPF and LC, and 83 (17.9%) 
were diagnosed with LC before IPF. Patients were classified as having a “simultaneous diagnosis” if LC was diag-
nosed within 3 months of IPF being diagnosed. Patients diagnosed with IPF more than three months in advance 
of the LC diagnosis were classified into the “IPF in advance” group, while those who were diagnosed with LC 
more than three months in advance of IPF were classified into the “LC in advance” group. The baseline demo-
graphics of the IPF with LC group, according to the order of diagnosis, are shown in Supplementary Table S1. 
There was no significant difference in the baseline demographics across the three groups, including age, sex, 
region of residence, and household income.
Incidence of IPF and IPF with LC. Between 2012 and 2016, the incidence of IPF increased. In 2012, 
the incidence of IPF was 2.5 per 100,000 population in Koreans aged ≥ 40 years; this value increased to 3.8 per 
100,000 in 2016. The number of IPF with LC patients was 32 cases in 2012 and 118 cases in 2016 (Fig. 1). The 
cumulative incidence rates of LC in the IPF patients who did not have LC at the time of IPF diagnosis were 1.7%, 
4.7%, and 7.0% at 1, 3, and 5 years, respectively (Fig. 2). The median time from IPF diagnosis to LC development 
was 16.3 (Interquartile range [IQR], 8.2–28.8) months. In the comparison conducted by age group, the median 
time from IPF diagnosis to LC development was not significantly different (P = 0.852, Table 2).
Mortality. In the total 7277 IPF patients, 1- and 2-year survival rates were 77.7% and 66.3%, respectively. In 
Kaplan–Meier analysis, survival rates were significantly lower in the IPF with LC group than in the IPF without 
Table 1.  Baseline characteristics of IPF patients with or without LC, 2012–2016. a Household income decreases 
from the 1st to the 5th quintile. Values are expressed as means ± standard deviations or numbers (%). IPF 
idiopathic pulmonary fibrosis, LC lung cancer.
Total IPF without LC IPF with LC P value
Total, n (%) 7277 (100.0%) 6813 (93.6%) 464 (6.4%)
Male, n (%) 5499 (72.8%) 5069 (74.4%) 430 (92.6%) < 0.001
Age
Mean 71.5 ± 9.0 71.5 ± 9.0 70.6 ± 8.0 0.029
40–49 years 91 (1.3%) 88 (1.3%) 3 (0.6%) < 0.001
50–59 years 628 (8.6%) 593 (8.7%) 35 (7.5%)
60–69 years 2098 (28.8%) 1933 (28.4%) 165 (35.6%)
70–79 years 3132 (43.0%) 2924 (42.9%) 208 (44.8%)
≥ 80 years 1328 (18.3%) 1275 (18.7%) 53 (11.4%)
Region of residence, n (%)
Urban 3262 (44.8%) 3040 (44.6%) 222 (47.8%) 0.177
Rural 4015 (55.2%) 3773 (55.4%) 242 (52.2%)
Household incomea, n (%)
1st quintile 1193 (16.4%) 1137 (16.7%) 56 (12.1%) 0.089
2nd quintile 850 (11.7%) 795 (11.7%) 55 (11.8%)
3rd quintile 903 (12.4%) 849 (12.5%) 54 (11.6%)
4th quintile 1315 (18.1%) 1227 (18.0%) 88 (19.0%)
5th quintile 3016 (41.4%) 2805 (41.2%) 211 (45.5%)
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LC group [log-rank test, P < 0.001; Fig. 3]: 1- and 2-year survival rates were 65.5% and 44.2% in the IPF with LC 
group and 78.5% and 67.8% in the IPF without LC group, respectively. In multivariate Cox proportional hazard 
analysis, the presence of lung cancer (hazard ratio [HR] 2.922, P < 0.001) and age at the diagnosis of IPF (HR 
1.042, P < 0.001) were independent risk factors for mortality in IPF patients (Table 3).
Discussion
In the present study, we estimated the cumulative incidence of LC in IPF patients and mortality associated LC 
in IPF patients using a nationwide database. Our data showed that the cumulative incidence rates of LC in IPF 
patients who did not have LC at IPF diagnosis were 1.7%, 4.7%, and 7.0% at 1, 3, and 5 years, respectively. The 











































Figure 1.  Incidence of IPF and the number of IPF with LC patients between 2012 and 2016. (a) Incidence of 
IPF. (b) The number of IPF with LC patients. IPF idiopathic pulmonary fibrosis, LC lung cancer.
Figure 2.  Cumulative incidence of LC in IPF patients. IPF idiopathic pulmonary fibrosis, LC lung cancer.
Table 2.  Time from IPF diagnosis to LC development according to age group. Values are expressed as medians 
(interquartile range). IPF idiopathic pulmonary fibrosis, LC lung cancer.
N Time (months) P value
Total 254 16.3 (8.2–28.8) 0.852
40–59 years 21 16.4 (63.8–29.8)
60–69 years 95 18.9 (9.3–28.0)
70–79 years 116 15.7 (7.9–28.9)
 ≥ 80 years 22 14.3 (7.0–27.9)
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and 44.2% in the IPF with LC group, which were significantly lower than those in the IPF without LC group. 
This study is meaningful as the largest to estimate the cumulative incidence of LC in IPF using nationwide data.
Although epidemiological studies have revealed that IPF is an independent risk factor for LC development, 
the pathogenesis connecting the two diseases is poorly understood. According to the existing literature, LC and 
IPF share the following pathogenetic mechanisms in terms of their development: genetic alterations including 
micro-satellite instability, loss of gene heterozygosity and gene mutations including those of p53; alteration of 
epigenetics; abnormal expression of microRNAs; cellular and molecular aberrances such as an altered response 
to regulatory signals and reduced cell-to-cell communication; and activation of specific signaling transduction 
 pathways19–22. The most frequently observed histologic LC type in IPF patients was squamous cell carcinoma 
followed by adenocarcinoma; adenocarcinoma is the most commonly observed histologic type in the general 
 population6–8,10–13,23. LC in IPF is typically observed in the peripheral zone of the lower lung in the fibrotic  area24.
Few studies have reported on the incidence of LC during the follow-up period for IPF. Ozawa et al. reported 
cumulative LC incidence rates of 3.3%, 15.4%, and 54.7% at 1, 5, and 10 years, respectively, in 103 IPF  patients10. 
Kato et al. demonstrated incidences of 12.2% and 23.3% at 5 and 10 years, respectively, in 632 IPF  patients7. 
Tomasetti et al. showed that among 181 IPF patients, 16 were diagnosed with LC during the follow-up period 
for IPF. In that study, the median duration from IPF diagnosis to LC development was 30.0 (IQR, 27.5–84.1) 
months, and 81.8% of the IPF patients with LC developed LC in 3 years from IPF  diagnosis8. However, each 
of the three aforementioned studies was conducted at a single center. Yoon et al. conducted a study based on 
interstitial lung disease registry data in the United States, which included 1108 IPF patients, and reported that 
the median time from IPF diagnosis to LC development was 53.0 (IQR, 25.0–77.0) months, and the incidence 
of LC increased in the first two years after IPF diagnosis, which persisted until year  four13. The present study 
is the largest nationwide cohort study to date based on the NIHS database of almost all South Korean citizens 
aged ≥ 40 years (about 50 million people) and included 7277 IPF patients from this population. In this study, 
the cumulative incidence rates of LC in IPF at 1, 3, and 5 years of 1.7%, 4.7%, and 7.0%, respectively, were lower 
than those observed in previous studies. IPF shows a varied natural course after  diagnosis18; therefore, patients 
who visit hospitals routinely and are enrolled in study registries from previous studies may have a relatively 
severe and rapid progressive disease course. This may be the reason for the lower incidence observed in our 
population-based study, which is based on the NHIS database of almost all Korean citizens, and also a strength 
of this study compared to previous studies.
Figure 3.  Kaplan–Meier survival curves of all-cause mortality in IPF with LC, and IPF without LC. IPF 
idiopathic pulmonary fibrosis, LC lung cancer.
Table 3.  Cox proportional hazard regression analysis for mortality in IPF patients. CI confidential interval, 
HR hazard ratio.
HR (95% CI) P value
Lung cancer 2.922 (2.054–2.557) < 0.001
Age (year) 1.042 (1.038–1.046) < 0.001
Sex (male) 0.932 (0.862–1.008) 0.079
Region of residence (urban) 0.936 (0.874–1.001) 0.054
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The cumulative incidence graph showed a constant incidence rate over the 5-year study period, while previ-
ous studies reported that the incidence rate increased until 3–4 years from IPF diagnosis and then  decreased8,13. 
The median time from IPF diagnosis to LC development tended to be shorter in those aged ≥ 60 years, but there 
was no significant difference between the age groups.
Although there is no official guideline for LC surveillance till date, various suggestions have been proposed in 
previous reviews. Tzouvelekis suggested the performance of high-resolution computed tomography (HRCT) once 
a year in all IPF patients. For nodules with a diameter smaller than 8 mm, HRCT is suggested every 3–6 months. 
If HRCT shows progression of the nodule, and for nodules with a diameter of at least 8 mm, positron emission 
tomography-CT is  recommended25. Lederer et al., in another review, proposed that annual low-dose CT should 
be performed according to the U.S. Preventive Services Task Force criteria for LC screening, and nodules should 
be managed according to risk group based on the established guidelines of the Fleischner  Society1.
Considering previous reports, which state that the LC incidence in IPF patients is approximately eight times 
higher than in the general population after adjusting for smoking  history3, and the fact that the cumulative 
incidence rate was kept constant during the study period, it is suggested that all IPF patients undergo close 
HRCT screening.
Another challenge associated with IPF in LC, in real clinical practice, is the identification of whether the 
antifibrotic agents that are used to reduce the degree of forced vital capacity decline in IPF patients have anti-
cancer effects. Nintedanib and pirfenidone are two antifibrotic agents that have been approved for IPF treatment. 
A preclinical experimental study revealed that a combination of cisplatin and pirfenidone increases cell death 
rates and decreases cancer progression  rates26. A retrospective study reported that the incidence of LC was lower 
in IPF patients receiving  pirfenidone27. Nintedanib was first approved in combination with docetaxel as a second 
line treatment for advanced non-small cell  LC28. The anti-cancer effect of these two antifibrotic agents should be 
further investigated in both therapeutic and protective aspects.
This study has several limitations. First, we defined IPF using the ICD-10 code assigned by healthcare provid-
ers; this may have reduced the diagnostic accuracy owing to inconsistencies with the diagnostic criteria defined 
by the International Consensus Statement of the American Thoracic Society and European Respiratory Society 
in  201129. However, IPF is classified as a rare intractable disease in Korea and strictly controlled by the Korean 
NHIS for medical cost reductions. This may lead physicians to enter the diagnostic code with care. Second, data 
on confounding factors that may have affected the incidence and mortality of both IPF and LC, such as smok-
ing, pulmonary function (forced expiratory volume in one second and forced vital capacity), and concomitant 
emphysema, were not available in the study. Further study is needed to confirm whether close HRCT surveillance 
for LC in IPF will help improve the mortality of IPF patients with LC.
In conclusion, the present study revealed that the prevalence of LC in IPF patients was 6.4% and the cumula-
tive incidence rates were 1.7%, 4.7%, and 7.0% at 1, 3, and 5 years, respectively, after IPF diagnosis. The 5-year 
survival rate was 15.6% in the IPF with LC group, which was significantly lower than that in the IPF without LC 
group. Our findings suggest the need for close HRCT surveillance for LC in all IPF patients.
Methods
Data source. The National Health Insurance Service (NHIS) in Korea has provided health insurance ser-
vices to all Korean citizens living in Korea since 2000. Consequently, a large amount of health-related data has 
accumulated in the NHIS database. To offer relevant and useful data for health researchers, the NHIS established 
a population database including data on socioeconomic status (household income), medical treatments, medi-
cal care institutions, and general health examinations since 2002. From the NHIS database, we identified IPF 
and LC based on International Classification of Disease, Tenth Revision (ICD-10) diagnostic codes. This study 
was approved by the Institutional Review Board and Ethics Committee of National Health Insurance Service 
of the Ilsan Hospital (IRB number: NHIMC 2019-1-291). All methods were performed in accordance with the 
Declaration of Helsinki.
Case identification. The NHIS database includes medical data on almost all South Korean citizens 
aged ≥ 40 years (about 50 million people) between 2011 and 2016. From this population, we identified patients 
visiting medical institutions with a diagnosis of IPF, coded as J84.18 according to the ICD-10. We excluded 
patients with ICD-10 codes for both IPF and connective tissue disease, owing to the possibility of interstitial 
lung disease being related to connective tissue disease. The ICD-10 codes for connective tissue disease were as 
follows: M05 for rheumatoid arthritis, M07 for psoriatic and enteropathic arthropathies, M30 for polyarteritis, 
M31 for other necrotizing vasculopathies, M32 for systemic lupus erythematosus, M33 for dermatopolymyosi-
tis, M34 for systemic sclerosis, M35 for other systemic involvement of connective tissue, and M45 for ankylosing 
spondylitis. The code J84.18 was classified as a rare intractable disease, and patients assigned to this code receive 
medical cost reductions from the NHIS by up to 10% of the total cost. Owing to the financial problems associ-
ated with rare intractable diseases, the ICD for these diseases has high sensitivity and  specificity30. The ICD-10 
code C34 was used for malignant neoplasms of the bronchus and lung. To estimate the cumulative incidence 
of LC in patients with newly diagnosed IPF and the time from IPF diagnosis to LC development, we excluded 
patients who were diagnosed with IPF in 2011 and analyzed those who were newly diagnosed with IPF after 
2012. Mortality data were analyzed from 2012 to 2018.
Statistical analysis. Continuous variables were analyzed using the Student’s t-test, and categorical vari-
ables using Chi-squared distribution. Cumulative time-to-event distributions were estimated using the Kaplan–
Meier method. Log-rank test was used to compare survival curves, and Cox proportional hazards regression 
analyses were conducted to assess the impact of LC on survival in IPF. In all cases, P values < 0.05 were consid-
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ered statistically significant. All statistical analyses were performed using the SAS program, version 9.4 (SAS 
Institute, Cary, NC, USA).
Ethics approval and consent to participate. This study was approved by the Institutional Review 
Board and Ethics Committee of National Health Insurance Service of the Ilsan Hospital (IRB number: NHIMC 
2019-1-291). Written informed consent was waived as the nature of retrospective study by IRB.
Data availability
The datasets used and analyzed in the current study are available from the corresponding author on reasonable 
request.
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